SCM
VRNA

Soleus Capital Management’s Verona Pharma VRNA Stock Holding History

Soleus Capital Management’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-21,700
Closed -$459K – 117
2023
Q2 		$459K Buy
+21,700
New +$463K 0.05% 97

Other funds holding VRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Soleus Capital Management's VRNA Position: Q3 2023 in Review

Soleus Capital Management sold out of Verona Pharma (VRNA) in Q3 2023, closing a stake of 21,700 shares — an estimated $459K sold.

Soleus Capital Management first reported a position in VRNA in Q2 2023 and held it in 1 quarter. The position peaked at $459K in Q2 2023. 102 funds tracked by Wall St. Rank hold VRNA as of Q3 2023.

  • Soleus Capital Management reported no remaining Verona Pharma position as of Q3 2023 after selling out during the quarter.
  • Soleus Capital Management sold 21,700 Verona Pharma shares in Q3 2023, an estimated $459K.
  • Soleus Capital Management first reported a position in Verona Pharma in Q2 2023 and held it in 1 quarter.
  • Soleus Capital Management's Verona Pharma position peaked at $459K in Q2 2023.
  • 102 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2023.

Based on Soleus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.